SCHEMBL6964063

SCHEMBL6964063

N[C@@H](CC(=O)O)C(=O)NCCCc1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.63
CYP2C9 P11712 1/20 0.63
CYP2C19 P33261 1/20 0.63
KMT2A Q03164 1/20 0.63
CNR1 P21554 3/20 0.61
MMP8 P22894 3/20 0.58
HDAC8 Q9BY41 1/20 0.57
KDM4A O75164 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.55
NPC1 O15118 1/20 0.54
RAB9A P51151 1/20 0.54
GAA P10253 1/20 0.54
HPGD P15428 1/20 0.54
CNR2 P34972 2/20 0.53
EPHX2 P34913 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL7955825 0.92 CYP2D6 (0.55) CYP2D6CYP2C9CYP2C19KMT2ACNR1
SCHEMBL24322367 0.91 POLB (0.54) CYP2D6CYP2C9CYP2C19KMT2ACNR1
SCHEMBL11710494 0.91 POLB (0.54) CYP2D6CYP2C9CYP2C19KMT2ACNR1
Hydrochloric Acid SCHEMBL11100779 0.85 CYP2D6 (0.63) CYP2D6CYP2C9CYP2C19KMT2ACNR1
SCHEMBL7955831 0.82 CYP2D6 (0.50) CYP2D6CYP2C9CYP2C19KMT2ACNR1
SCHEMBL10627851 0.81 KMT2A (0.77) CYP2D6CYP2C9CYP2C19KMT2ACNR1
SCHEMBL10611159 0.81 KMT2A (0.77) CYP2D6CYP2C9CYP2C19KMT2ACNR1
SCHEMBL10423181 0.81 KMT2A (0.77) CYP2D6CYP2C9CYP2C19KMT2ACNR1
SCHEMBL10626768 0.81 DPP7 (0.63) CYP2D6CYP2C9CYP2C19KMT2ACNR1
SCHEMBL10626773 0.81 DPP7 (0.63) CYP2D6CYP2C9CYP2C19KMT2ACNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220122691-A1 HtrA Inhibitors and CagA Inhibitors and Use Thereof Psomagen Inc. (US) 2022-04-21 US disclosed
EP-1098878-B1 BISPIPERIDINES AS ANTITHROMBOTIC AGENTS CEPHALON FRANCE (FR) 2003-12-17 EP disclosed
EP-1098878-A1 BISPIPERIDINES AS ANTITHROMBOTIC AGENTS LABORATOIRE L. LAFON (FR) 2001-05-16 EP disclosed
WO-2000003986-A1 BISPIPERIDINES AS ANTITHROMBOTIC AGENTS LABORATOIRE L. LAFON (FR) 2000-01-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220122691-A1 HtrA Inhibitors and CagA Inhibitors and Use Thereof HTRA1, GIPR, HPN CYP2D6 4712/4885CYP2C9 4549/4885CYP2C19 4010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.